Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
StockNews.AI · 3 hours
AI Summary
Molecular Partners announced trial-in-progress posters for MP0712, a 212Pb-based Radio-DARPin targeting DLL3 in SCLC and DLL3-expressing tumors, at ASCO and SNMMI in 2026. The Phase 1/2a US study is actively recruiting with initial data expected in 2026; prior 203Pb imaging data and the Orano Med collaboration support continued clinical development.
Sentiment Rationale
Initial trial posters and a scheduled data readout can influence sentiment but are not guaranteed to move fundamentals until data are disclosed; historically, early-phase radiopharmaceutical readouts can cause volatility but require positive safety/efficacy signals to meaningfully lift valuation.
Trading Thesis
Bullish over 12–18 months if MP0712 data show favorable safety/early efficacy signals.
Market-Moving
- ASCO 2026 (May 29–June 2) and SNMMI 2026 (May 30–June 2) presentations.
- Phase 1/2a MP0712 data readout anticipated in 2026.
- Orano Med collaboration could lift milestones and collaboration value.
- >85% DLL3 expression in SCLC suggests a sizable addressable market.
Key Facts
- MP0712 is a 212Pb-based Radio-DARPin therapy for DLL3.
- US Phase 1/2a trial actively recruiting; initial data expected in 2026.
- Trial posters at ASCO 2026 and SNMMI 2026 to share progress.
- Orano Med co-development; imaging data with 203Pb supports efficacy.
- DLL3 expressed in >85% of SCLC tumors; addressable neuroendocrine cancers.
Companies Mentioned
- Molecular Partners AG (MOLN): Clinical-stage biotech; MP0712 is a lead Radio-DARPin program; potential near-term catalysts from trial updates.
- Orano Med (N/A): Strategic partner for MP0712; collaboration could influence milestones and future funding.
Corporate Developments
Corporate Developments: The news centers on clinical-candidate progress and a strategic partnership, signaling potential value realization if trial data are favorable.